Search PubMed⌕ Search

Biomedical subjects

D Eccleston

Publications and source records attributed to D Eccleston.

At least 37 records · Page 2Linked to original sources

Treatment, prediction of relapse and prognosis of chronic primary major depression.

Our study of chronic and non-chronic depressive patients suggests that the following individual factors may predispose a patient to develop chronicity: unipolar depression, neurotic premorbid personality, high familial loading for affective disorder and multiple life events before and after the onset of the illness episode. It is interesting to note that bipolar disorders appear to be under-represented. This may be due to symptomatic chronicity in bipolar illness being more often represented by rapid cycling disorder. Evidence from a group of prospectively ascertained depressives with a median duration of illness of one year showed that apparently 75% of the variance in length of illness episode can be explained. Thus time taken to introduce active treatments, premorbid neuroticism, the occurrence of life events before and after the onset of illness, age at onset of first illness episode and family history of affective disorders were confirmed as important predictor variables. The fact that 85% of patients who develop chronic primary major depressive disorders have previously had an episode of affective illness tends to militate against the stereotype of these patients having a personality disorder. In future, it is important that biological research (for example, neuroendocrine studies) is directed towards chronically depressed patients. In the past, these patients have tended to be excluded from such studies as they represent an atypical population. It is therefore quite clear that future research should be directed towards not only pharmacological but also psychological and social mechanisms which lead to the perpetuation of depressive illness.

Adult↗

A double-blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia.

Sixty-one patients with acute schizophrenia received either remoxipride (75-375 mg daily) or thioridazine (150-750 mg daily) for 6 weeks. There was no statistically significant between-drug difference in improvement in mental state, as measured by the Brief Psychiatric Rating Scale, although the trend favoured thioridazine; global assessment of illness severity at the last rating also favoured thioridazine. Sedation, anticholinergic effects, autonomic dysfunction, and weight gain were significantly more common in patients receiving thioridazine. Both drugs produced few extrapyramidal effects, but both were associated with cardiovascular changes in two patients; neither drug produced significant abnormalities in laboratory tests.

Acute Disease↗

A multiple timepoint study of N-terminal pro-opiomelanocortin in depression using a two-site recognition immunoradiometric assay.

N-pro-opiomelanocortin (N-POMC) is secreted from the same precursor as ACTH and beta-endorphin. Elevated plasma ACTH and beta-endorphin/beta-lipotrophin concentrations have been reported in depression, however there have been no previous studies of N-POMC. Twenty-five patients with major depression and 18 control subjects were studied at five timepoints to examine diurnal rhythm and the effect of a dexamethasone suppression test. N-POMC was measured using a newly developed two-site recognition immunoradiometric assay (IRMA). This demonstrated advantages of sensitivity, specificity and simplicity compared with existing radioimmunoassays. N-POMC exhibited a pattern of diurnal rhythm and suppression in response to dexamethasone as described for other POMC derived peptides. Depressed subjects had higher levels of N-POMC at 0900 h post-dexamethasone than did control subjects. In conclusion, the results of this study are consistent with a hypothesis of cosecretion of POMC-derived peptides. N-POMC has a similar pattern of abnormal concentrations to ACTH and beta-endorphin/beta-lipotrophin in depression. This constitutes probable evidence of POMC-derived peptide resistance to glucocorticoid feedback in this condition.

Adult↗

A double blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia.

This is the first comparative double blind study of remoxipride. Sixty-one patients with acute schizophrenia received either remoxipride (75-375 mg daily) or thioridazine (150-750 mg daily) for 6 weeks. There was no statistically significant between-drug difference in improvement in mental state, as measured by the Brief Psychiatric Rating Scale, although the trend favoured thioridazine; global assessment of illness severity at the last rating also favoured thioridazine. Sedation, anticholinergic effects, autonomic dysfunction and weight gain were significantly more common in patients receiving thioridazine. Both drugs produced few extrapyramidal effects, but both produced cardiovascular changes in two patients; neither drug produced significant abnormalities in laboratory tests.

Acute Disease↗

The Newcastle Chronic Depression Study. Patient characteristics and factors associated with chronicity.

Chronic depression is defined as "symptomatic non-recovery for a period of 2 or more years". Chronic primary major depressives (n = 24) were compared retrospectively with a control group of primary major depressives (n = 20) who had recovered from their illness episode within 2 years. The former had a significantly higher familial loading for affective disorder and showed an increased incidence of independent undesirable life events during the 6 months prior to and 2 years after the onset of their illness. Female chronic depressives also had a significantly greater number of previous illness episodes and a more frequent history of thyroid dysfunction. Personality as measured on the EPO, psychiatric problems arising as secondary complications of the depressive illness, and developmental object loss did not differentiate chronic from non-chronic depressives.

Adult↗

Whole blood serotonin and plasma tryptophan using high-pressure liquid chromatography with electrochemical detection.

Methods are detailed for whole blood serotonin (5-HT), equivalent to platelet 5-HT, and plasma tryptophan. These assays may be carried out on the same blood sample which need be no more than 1 ml, are rapid, and avoid the difficulties, such as protein precipitation and fluorophor formation, encountered in other methods. The linearity of the methods is extensive and allows for accurate measurement of low concentrations. Data are given for normal humans and for patients receiving psychiatric treatment for depression.

Adult↗

The Newcastle chronic depression study: results of a treatment regime.

A trial is described of new therapeutic approaches in treatment-resistant chronic depression. Phenelzine, L-tryptophan and lithium ("5HT-cocktail") was used as the major pharmacological strategy, and a regime aimed at reducing vanadium concentrations was added in the second part of the trial. Patients were randomly assigned to cognitive behaviour therapy in addition. All but 1 of the patients who ultimately entered the trial were unipolar depressives; 2 bipolar patients were withdrawn in the initial drug-free period because of the development of mixed affective states. Eleven of 20 patients showed an improvement to less than 50% of their initial scores on the Hamilton Rating Scale for Depression, and all those who improved did so in the first 6 weeks. Cognitive behaviour therapy did not seem to influence the response, but it is recognized that the short duration of therapy may be inadequate in these circumstances. It is suggested that intensive drug treatment is a necessary preliminary in management and may allow the effective use of rehabilitation aimed at the secondary handicaps of chronic depression.

Adult↗

Vaginal absorption of naproxen.

The vaginal absorption of the drug naproxen was investigated in five healthy pre-menopausal women. It was found that naproxen was absorbed, but not to therapeutically useful levels.

Absorption↗

An open multicentre study of the treatment of florid schizophrenia with remoxipride.

Remoxipride, a novel substituted benzamide, was given for 4 weeks to 18 florid schizophrenics in an open study. The mental state of the majority improved as measured by the Brief Psychiatric Rating Scale. Remoxipride itself did not appear to cause troublesome extrapyramidal effects. There were no significant adverse effects on the cardiovascular system and no significant abnormalities in laboratory tests. These results suggest that remoxipride has antipsychotic effects, and that this should be tested in controlled clinical trials.

Adolescent↗

Alaproclate--an open clinical study in depressive illness.

This open study of alaproclate points towards an antidepressant effect in a a relatively chronic and drug-resistant group of depressives. Five patients had an average improvement of more than 21 points on the Hamilton Rating Scale for Depression and six had an average improvement of seven points. Several patients had anticholinergic side effects, abnormal results in liver functional tests and faecal occult blood, but none were bad enough to require being taken off the drug and most side effects improved before the end of the trial. The biochemical results suggested that the responders and non-responders constituted two distinct biological groups. In the patients who responded well to treatment there were increases in Km values consistent with treatment. The Km and 5-HT values correlated strongly with plasma drug values. There was a strong correlation between Hamilton Rating scores in the 4th week and Km values in the 4th week, although there were only five cases. However, there were no significant relationships between improvement and any pretreatment value. These results are sufficiently promising to suggest that a controlled clinical trial would yield information on alaproclate as a therapeutic aid.

Adult↗

Serum concentration of depot neuroleptics in tardive dyskinesia.

Using radioimmunoassay techniques, serum levels of depot neuroleptics, fluphenazine and flupenthixol, were estimated in two groups of chronic schizophrenic patients with, and without, tardive dyskinesia. There were high significant difference in dose-related serum levels of either drug between the groups. The hypothesis that patients with tardive dyskinesia develop the syndrome because they do not metabolise neuroleptics as efficiently as those without the syndrome was not supported by the data.

Dyskinesia, Drug-Induced↗